StockWatch
·
NEWGEN · Q2 FY-2027 · PREVIEW

Newgen on the test: Can annuity momentum and large order pipeline offset FII exit?

Fresh deal momentum in US healthcare and Middle East, but execution risk under new CEO and amid FII retreat. Watch annuity growth and order recognition timing.

Q2 FY27 resultsNEWGENNewgen Software Technologies Ltd18 Oct 2026 · 3 min read

What matters in this quarter

For a B2B software company serving BFSI and insurance, the story is annuity revenue — the stable, recurring cloud and maintenance base that funds growth and justifies valuation. In Q1, Newgen's annuity grew 14% YoY to ₹254 Cr, proof that large deals signed in recent quarters are moving into revenue. Q2 will test two things: (1) Can annuity sustain double-digit growth as the FY27 order pipeline (US $5.48M healthcare, Qatar $1.79M, Kuwait, UK, Annapurna) starts flowing? (2) Can margin expansion hold at 20%+ EBITDA despite FII selling pressure, a weakening stock, and the operational friction of CEO transition?

What to expect

Revenue from operations

~₹362 Cr

Implies ~1% QoQ growth, +11-12% YoY; trajectory steady after Q1's 11% YoY

Annuity revenue

~₹264 Cr

+12-15% YoY growth; the true barometer of deal traction flowing through the P&L

EBITDA margin

~21-22%

FY27 guided 20-25%; Q1 implied ~23%, Q2 seen holding if opex discipline intact

PAT (Consolidated)

~₹62-65 Cr

Q1 grew 26% YoY to ₹63 Cr; expect modest growth from margin and scale

A strong quarter means annuity accelerates into 15%+ YoY, the US healthcare deal (recognized in phases over 3 years) starts showing initial revenue, and EBITDA margin stays above 22%. It signals that order pipeline is converting and execution under the new CEO is intact. A weak quarter would see annuity slow to mid-single digits YoY (demand weakness), large deals (US, Qatar, Kuwait) show minimal Q2 recognition (timing push to Q3), or margins compress below 20% (cost bloat or FX headwind). Either would spoil the guidance narrative.

On track to FY27 guidance?

Q1 delivered ₹357 Cr revenue (+11% YoY) and ₹63 Cr PAT (+26% YoY), tracking squarely for 20-25% EBITDA margin and double-digit revenue growth for the full year. For H1 to average 11% growth, Q2 needs to stay flat-to-slightly-positive YoY (around ₹360 Cr), which is on plan. The risk is not the run-rate but order recognition timing — large deals won in Q2 (US Sep 28, Qatar Sep 21, Kuwait Jun 30, UK Oct 16) have long implementation periods, so upside from these may load into H2 more than H1. Street expects this; the test is whether management reclares confidence in hitting 20%+ EBITDA margins.

What the Street is saying

Since last quarter: The filings scan

Material business updates and governance notes
  • 1 · Large deal wins anchor next 18 months

    US health insurer contract ($5.48M, Sep 28) — NewgenONE Complaints, Appeals & Grievances (CAG) solution, 3-year cloud-hosted deal. Highest single-deal value in recent periods; ensures stable recurring annuity. Qatar contract ($1.79M, Sep 21) core insurance platform. Kuwait (₹26.7 Cr equiv) and UK (£1.63M) also signed. Positive signal: deal size and pipeline strength; risk: all multi-year, so upfront revenue recognition may disappoint if clients push go-live dates.

  • 2 · Management transition and CEO changeover

    Tarun Nandwani appointed CEO (Jul 2, 2026), replacing prior leadership. EVP Surender Jeet Raj (Global Business Strategy & HR) retired (Oct 12) — a long-tenured KMP. CMD Diwakar Nigam was indisposed for 45+ days (Jun 30). Signaling friction: veteran departures during a pivotal growth quarter. Newgen must prove governance continuity and that order execution doesn't stall under new CEO.

  • 3 · FII selling and ownership shift

    FII holdings slid to 13.78% (Q1 FY27) from 14.28% prior quarter and 19.36% a year ago. Macro FII exit from India, but Newgen's pace steeper, hinting concern over execution. DII flat, promoter steady at 53.85%. Bulk deals in Jul (QE Securities, Microcurves) were neutral arbitrage trades. Stock down 72% from ATH of ₹1798.9; at ₹493.9 it's off the lows but still bearish-trending.

  • 4 · Trading window and result timing

    Trading window closed Sep 30 for Q2 results; board meeting scheduled Oct 23 to approve results. Routine governance.

The setup

Newgen is a high-order, high-annuity software player in a BFSI market that's digitizing. The big question is not whether the business is real — Q1's 26% PAT growth and ₹52.55 Cr US deal prove it — but whether order pipeline can convert under a new CEO while FII exits and macro headwinds persist. Street is constructively positioned (Buy consensus, 30%+ upside), but target cuts signal skepticism that management can deliver.

Three things to watch on result day

Key metrics and signposts
  • 1 · Annuity revenue — the pulse

    If annuity growth slows below 12% YoY, the order pipeline isn't flowing as expected. If it holds 14%+ (matching Q1), the US healthcare and Qatar deals are already seeding new bookings.

  • 2 · Order book guidance

    Management should reclare FY27 double-digit revenue growth and 20-25% EBITDA margin. Any qualification ('tight' macro, 'slower' deals) would be a warning.

  • 3 · CEO commentary on deal recognition

    Tarun Nandwani's first earnings call: Will he own the large US/Qatar/Kuwait deals and project confidence in H2 upside, or push recognition to FY28? Execution transparency will reset Street confidence.

Newgen's Q2 matters because it will be the first print under new CEO Tarun Nandwani and the test of whether Q1's order wins (US, Qatar, Middle East, UK) start flowing into the P&L on schedule. The Street consensus is Buy, but analyst target trims point to real execution risk. Annuity growth at 14%+ YoY and margins holding 21%+ would argue that the order pipeline is intact and the leadership handover is smooth. A miss would embolden the FII exit.

Informational and educational content only. Not investment advice.